Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Lilly 3Q11 | Contract Pharma

What are you searching for?

Sign in
Breaking News

Financial Report: Lilly 3Q11

Revenues up 9%

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Lilly 3Q11

3Q Revenues: $6.1 billion (+9%)

3Q Earnings: $1.2 billion (-5%)

YTD Revenues: $18.2 billion (+8%)

YTD Earnings: $3.5 billion (-11%)

Comments: Cymbalta sales were up 29% to $1.1 billion in the quarter. Humalog sales were up 20% to $593.2 million. Forteo and Strattera sales were also up 20% to $240.3 million and $153.2 million, respectively. Cialis sales were up 16% to $469.8 million. Alimta sales were up 12% to $629.7 million. Gemzar sales dropped 72% to $91.0 million due to generic competition. U.S. revenues increased 4% to $3.3 billion. Revenue outside the U.S. increased 15% to $2.9 billion due to the positive impact of foreign exchange and increased volume.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters